MetaCap

Kyverna Therapeutics (KYTX) vs Ocugen (OCGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ocugen (OCGN) has outperformed Kyverna Therapeutics (KYTX) over the past year, losing 33.8% versus a loss of 39.9%. Kyverna Therapeutics is the larger company by market cap ($269.3 million vs $260.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYTX-39.92%OCGN-33.80%
+121%+37%-48%
Nov 21, 20251 yearNov 20, 2026
KYTX-85.85%OCGN+42.73%
+384%+134%-117%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYTX versus OCGN key metrics
MetricKYTXOCGN
Share price$4.26$0.7679
Market cap$269.33M$260.55M
1-day change-2.52%+4.79%
YTD return-54.68%-43.12%
1-year return-39.92%-33.80%
5-year return—-88.09%
EPS (TTM)$-2.75$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.41M
Revenue growth (YoY)—+8.83%
Net income (latest FY)$-161.31M$-67.85M
Operating margin—-1425.70%
Net margin—-1537.41%
52-week high$13.67$2.73
52-week low$4.18$0.691
Distance from 52-week high-68.84%-71.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+613.62%+1484.84%
Average volume867.28K7.34M
Shares outstanding63.22M339.31M
Employees172116
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

KYTX vs OCGN FAQ

Which is bigger, Kyverna Therapeutics or Ocugen?

Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $269.33M compared with $260.55M for Ocugen (OCGN).

Which stock has performed better over the past year, KYTX or OCGN?

OCGN returned -33.80% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.

Are Kyverna Therapeutics and Ocugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons